semaglutides approved for weight loss FDA approves obesity drug that helped people cut 15% FDA Approves Oral Semaglutide: First
Description
This condition usually affects the vision in one eye and is not typically characterized by total blindness

Most GLP-1 medications offer flexibility with a 24-hour window around your regular injection time

It is also licensed for weight management in adolescents aged 12 years and above with obesity
Whats happening

However, people using GLP-1 medicines may notice changes in snoring or daytime alertness as weight and metabolic health change
